Pharma Agencies That Own Both Creative and Media: Worth the Risk?

Agencies combining creative and media in the regulated pharma space are solving a real structural problem: fragmented accountability. When the team writing the copy and the team buying the placements operate separately, compliance friction multiplies and campaign performance suffers. Integrated models collapse that gap, but they introduce a different set of risks, particularly in an environment where a single regulatory misstep can pull a campaign entirely.

The question for pharma marketing leaders is not whether integration is theoretically sound. It is whether a specific agency can actually execute both disciplines to the standard the category demands, without one function subsidising the other’s weaknesses.

Why the Integration Question Matters More in Pharma Than Anywhere Else

I have managed agency relationships across roughly 30 industries. The structural tension between creative and media teams is universal. But in pharma, the stakes of that tension are categorically different. A misaligned campaign in consumer retail costs you wasted spend and a weak quarter. A misaligned campaign in pharma can trigger a regulatory response, a product recall communication, or a legal review that pulls your entire media schedule.

That is not hypothetical. The FDA and equivalent bodies in other markets have enforcement mechanisms that create real business consequences for promotional material that strays outside approved labelling. When creative and media operate in separate agencies, you get a compliance relay race: the creative team submits copy for MLR review, the media team plans placements based on assumptions about what will be approved, and the two processes run on different timelines. The result is either a campaign that launches late, or one that launches with creative that was not optimised for the placements it is running in.

Integration, in principle, solves this. One team understands both the message and the medium. The creative brief accounts for the placement environment. The media plan accounts for the creative constraints. The MLR review process is built into the workflow rather than bolted onto the end of it.

In practice, whether any given agency delivers that depends entirely on how the integration was built.

The Two Ways Agencies Get to Integration, and Why It Matters

Most integrated pharma agencies arrived at their current structure through one of two routes. They either started as media agencies and acquired or built a creative capability, or they started as creative agencies and added media planning and buying. The origin matters because it determines where the cultural centre of gravity sits, and in a regulated category, culture is not a soft concern.

An agency that grew up in media will tend to treat creative as a production function. The strategists think in audiences, placements, and cost-per-action. Creative is what you need to fill the inventory you have already bought. In pharma, this creates a specific failure mode: the media team optimises for efficiency metrics that the creative team cannot consistently hit because the regulatory review process does not move at the speed of programmatic optimisation.

An agency that grew up in creative will tend to treat media as a distribution function. The strategists think in messages, audiences, and brand positioning. Media is where you put the work once it is made. In pharma, this creates a different failure mode: beautifully crafted campaigns that are technically compliant but placed in environments that undermine the message, or bought at rates that make the economics of the campaign unviable at the required reach.

I saw a version of this play out early in my career. I was handed a whiteboard pen at a brainstorm for a major drinks brand, more or less without warning, and had to run the room. The instinct was to default to what I knew best and paper over the gaps. That instinct is exactly what weak integrated agencies do. The good ones acknowledge where the centre of gravity sits and build genuine capability in the other direction, rather than pretending the gap does not exist.

If you are evaluating an integrated pharma agency, the question to ask is not “do you do both creative and media?” Every agency will say yes. The question is: “Show me a campaign where the media plan changed because of a creative constraint, and show me a campaign where the creative brief changed because of a media insight.” The answer to that question tells you whether integration is structural or cosmetic.

What Regulatory Constraints Actually Do to Creative Strategy

There is a version of pharma advertising that treats regulatory review as the enemy of good creative. The compliance team is cast as the people who strip the life out of campaigns, and the creative team is cast as the people who push boundaries until something gets through. This framing is not just unproductive. It is commercially dangerous.

The pharma brands with the most effective advertising do not treat regulatory constraints as obstacles. They treat them as design parameters. The constraint that you cannot make efficacy claims beyond what the label supports is not a creative limitation. It is a brief. The constraint that fair balance requirements must be met in a specific format is not a production headache. It is a layout specification.

Agencies that have genuinely internalised this produce work that is compliant by design rather than compliant by revision. The difference in campaign velocity is significant. A campaign that is designed within regulatory parameters from the first brief will clear MLR review faster, require fewer revision cycles, and launch closer to the planned date than a campaign that is designed without those parameters and then retrofitted to meet them.

For integrated agencies, this is a structural advantage. When the creative team and the regulatory affairs function are working in the same building, or at least within the same agency structure, the feedback loops are shorter. The creative director knows what the regulatory lead will flag before the formal review. That knowledge gets built into the work earlier. The media team, in turn, can plan with greater confidence that the creative will clear review on schedule, which means the media plan does not have to be rebuilt at the last minute around a delayed asset.

This is where BCG’s work on biopharma go-to-market strategy is instructive. The complexity of a pharma launch is not primarily a creative or a media problem. It is a coordination problem. The agencies that solve it best are the ones that reduce the number of coordination points, not the ones that add more specialists to manage them.

The Efficiency Argument for Integration, and Its Limits

The commercial case for integrated agencies in pharma is usually made on efficiency grounds. One agency relationship instead of two. Shared data and insights rather than siloed reporting. A single P&L conversation rather than two separate fee negotiations. These are real benefits, and they are not trivial in a category where the cost of a failed launch is measured in hundreds of millions.

But efficiency arguments have a ceiling in pharma that they do not have in other categories. The regulatory environment means that some processes cannot be accelerated beyond a certain point regardless of how well your agency is integrated. MLR review timelines are what they are. Label restrictions are what they are. The agency can make the process more predictable, but it cannot make it faster than the regulatory framework allows.

I spent several years managing agencies that were selling AI-driven personalisation as a solution to performance problems. The pitch was compelling: personalised creative at scale, massive efficiency gains, significant results. When I looked at the actual data, the performance improvement was real but the explanation was wrong. The AI had not solved a sophisticated optimisation problem. It had replaced genuinely poor creative with something slightly less poor, and the performance lifted accordingly. The baseline was so low that almost anything would have improved it.

The efficiency argument for integrated pharma agencies can have the same problem. If your current multi-agency model is genuinely dysfunctional, consolidating to a single integrated agency will improve performance. But the improvement will be a function of fixing the dysfunction, not a function of integration being inherently superior. If your current model is well-managed, the efficiency gains from integration may be smaller than the agency pitching you suggests.

This is worth understanding before you make a structural change that will take 18 months to bed in and another 12 months to properly evaluate. The complexity of go-to-market execution in regulated categories means that agency transitions carry real switching costs, and those costs are not always reflected in the efficiency projections agencies present at pitch.

How to Evaluate an Integrated Pharma Agency Before You Commit

If you are a pharma marketing leader considering moving to an integrated model, the evaluation process needs to go deeper than a credentials presentation and a chemistry meeting. There are specific things to test.

First, ask to see the agency’s MLR process documentation. Not a slide about how they approach regulatory compliance. The actual process document, with timelines, owners, and escalation paths. An agency that has genuinely built regulatory capability into its workflow will have this. An agency that treats compliance as someone else’s problem will not.

Second, ask for a case study where the campaign did not go to plan and explain what happened. This is not a trick question. It is a diagnostic. Agencies that have genuinely operated in the pharma space for long enough will have examples of campaigns that hit regulatory obstacles, had label changes mid-flight, or had to be pulled and rebuilt. How they handled those situations tells you more about their operational capability than any success story.

Third, ask the creative director and the head of media planning to walk you through a brief together, without a prepared presentation. Watch how they interact. If the creative director defers every media question to the media lead and vice versa, the integration is positional rather than functional. If they finish each other’s sentences and challenge each other’s assumptions in real time, the integration is genuine.

Fourth, ask about data infrastructure. In pharma, the data environment is more restricted than in consumer categories. Patient privacy regulations, restrictions on targeting based on health conditions, and limits on the use of first-party data all constrain what is possible. An agency that has built its media capability in less regulated categories may not have the data architecture to operate effectively in pharma. This is a more common gap than agencies typically acknowledge.

Understanding how your agency partner fits into a broader go-to-market and growth strategy is the frame that makes these evaluation questions useful. Integration is a means to an end, not an end in itself. The end is a campaign that reaches the right patients and healthcare professionals, with a message that clears regulatory review, in placements that are appropriate to the audience and the message.

The Concentration Risk Nobody Talks About

There is a risk in the integrated model that rarely comes up in agency pitches, which is itself a reason to raise it. When you consolidate creative and media to a single agency, you create a single point of failure across both functions.

In a multi-agency model, if your media agency underperforms, you can replace it without disrupting your creative output. If your creative agency loses the key people on your account, you can manage the transition without pulling your media plan. The agencies are independent, and their failures are contained.

In an integrated model, a significant problem at the agency level affects everything simultaneously. A key account team departure, a conflict of interest with a competing pharma client, a regulatory finding against the agency itself, any of these can compromise both your creative pipeline and your media execution at the same time.

This is not an argument against integration. It is an argument for building the right contractual and operational safeguards into the relationship from the start. Transition clauses, IP ownership provisions, data portability requirements, and clear escalation paths to senior agency leadership are not bureaucratic formalities. In a regulated category where campaign continuity has direct implications for patient access to information about their treatment options, they are commercial necessities.

The broader question of how pharma brands structure their agency ecosystem fits within a wider set of decisions about market penetration and growth strategy. Market penetration frameworks are useful here because they force the question of whether your agency structure is optimised for the growth stage you are actually in, not the growth stage you were in when you last reviewed your agency roster.

What the Best Integrated Pharma Agencies Actually Look Like

Having seen agency models from both sides of the table, the integrated pharma agencies that consistently deliver share a small number of structural characteristics that are worth naming explicitly.

They have a dedicated regulatory affairs capability that sits within the agency, not outside it. Not a compliance consultant on retainer, not a relationship with a regulatory advisory firm. An in-house function that is present in creative briefings and media planning sessions, not just in the review stage.

They have a single data layer that feeds both creative and media decisions. This sounds obvious, but the operational reality in most agencies is that the creative team and the media team are working from different data sources, different dashboards, and different definitions of the same metrics. The agencies that have genuinely solved this have invested in the infrastructure to make it possible, and that investment shows up in the quality of the strategic recommendations they make.

They have leadership that has operated in the pharma category for long enough to have made real mistakes and learned from them. This is not a credential that shows up on a capabilities slide. It shows up in the questions the agency asks before they start work, in the assumptions they challenge in the briefing process, and in the contingency planning they build into every campaign timeline.

BCG’s research on coalition approaches to go-to-market strategy makes a point that is relevant here: the most effective marketing organisations build alignment between functions before they go to market, not during execution. In pharma, where execution windows are constrained by regulatory timelines and launch sequencing, that pre-market alignment is not a nice-to-have. It is the difference between a campaign that launches on schedule and one that does not.

The integrated agencies that deliver this are not necessarily the largest or the most decorated. They are the ones where the creative director and the head of media planning have been in the same room for enough years that they have built a shared language for the problems that only pharma marketers face.

If you are working through how agency structure fits into a broader commercial strategy, the Go-To-Market and Growth Strategy hub covers the wider set of decisions that sit around this one, from market entry sequencing to channel prioritisation to the organisational conditions that make any agency model work.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions